

CITATION REPORT

List of articles citing

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

DOI: 10.1111/bjh.12763

British Journal of Haematology, 2014, 165, 382-91.

Source: <https://exaly.com/paper-pdf/59479829/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
143	C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies. <i>PLoS ONE</i> , 2014 , 9, e95020	3.7	41
142	MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system. <i>PLoS ONE</i> , 2014 , 9, e114398	3.7	30
141	Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. 2014 , 2014, 90-9		93
140	Double-hit lymphomas: current paradigms and novel treatment approaches. 2014 , 2014, 107-12		33
139	'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. <i>British Journal of Haematology</i> , 2014 , 166, 369-74	4.5	39
138	MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. 2014 , 120, 3884-95		71
137	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014 , 45, 2144-53	3.7	30
136	Clinical and pathological features of Burkitt lymphoma showing expression of BCL2--an analysis including gene expression in formalin-fixed paraffin-embedded tissue. <i>British Journal of Haematology</i> , 2015 , 171, 501-8	4.5	14
135	Aggressive B-cell lymphomas: a review and practical approach for the practicing pathologist. 2015 , 22, 168-80		7
134	Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma. 2015 , 8, 2645-50		6
133	Tolosa-hunt syndrome in double-hit lymphoma. 2015 , 2015, 249891		4
132	ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?. 2015 , e449-57		68
131	Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 294-303	6.7	64
130	CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. 2015 , 126, 779-89		105
129	Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL. 2015 , 16, 58		28
128	Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. 2015 , 14, 207		107
127	Update in large cell lymphoma: understanding the pathology report. 2015 , 2015, 605-17		3

126	Genetic lesions in diffuse large B-cell lymphomas. 2015 , 26, 1069-1080		52
125	Beyond R-CHOP: treatment of double hit, tripple hit, MYC + NHL?. 2015 , 8, 48-51		0
124	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. 2015 , 33, 2848-56		236
123	Pathology of B-cell lymphomas: diagnosis and biomarker discovery. 2015 , 165, 27-50		8
122	Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations. 2015 , 32, 381-91		3
121	Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. 2015 , 16, e555-e567		108
120	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015 , 28, 1555-73	9.8	40
119	Diffuse large B-cell lymphoma and Burkitt lymphoma. 2015 , 21, 391-399		
118	Lymphoma and Lymphoproliferative Disorders. 2015 , 619-644		
117	De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis. 2015 , 32, 535-47		21
116	Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. 2015 , 17, 19-30		19
115	Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists. <i>Modern Pathology</i> , 2015 , 28, 545-51	9.8	27
114	A clinician's guide to double hit lymphomas. <i>British Journal of Haematology</i> , 2015 , 168, 784-95	4.5	52
113	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1742-9	1.9	9
112	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016 , 7, 2401-16	3.3	68
111	Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 324-34	6.7	40
110	Clinical approach to diffuse large B cell lymphoma. 2016 , 30, 477-491		19
109	Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. <i>British Journal of Haematology</i> , 2016 , 174, 686-91	4.5	26

108	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. 2016 , 108,		44
107	Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. 2016 , 23, 202-43		13
106	Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas. 2016 , 9, 41-54		4
105	An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. <i>Human Pathology</i> , 2016 , 48, 9-17	3.7	19
104	Double hit lymphoma: from biology to therapeutic implications. 2016 , 9, 669-78		19
103	Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era. 2016 , 6, e477		4
102	Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Lymphoid Neoplasms. 2016 , 9, 489-521		3
101	MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma. 2016 , 107, 853-61		32
100	A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients. 2016 , 55, 1126-1131		8
99	Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine. 2016 , 16, 1093-1102		3
98	High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. 2016 , 6, e491		4
97	Clinical and Pathologic Correlation of Increased MYC Gene Copy Number in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 679-683	2	7
96	Management of Patients with MYC-Altered Lymphomas. 2016 , 11, 208-17		5
95	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. 2016 , 3, e196-204		270
94	MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice. 2016 , 145, 166-79		22
93	MYC/BCL2 double-expression vs. cell-of-origin classification in diffuse large B-cell lymphoma: do we need to know both?. <i>Leukemia and Lymphoma</i> , 2016 , 57, 509-11	1.9	1
92	High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy. 2016 , 103, 210-8		7
91	Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. 2016 , 35, 1877-87		83

90	Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1640-8	1.9	8
89	Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1335-41	1.9	15
88	Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases. <i>Journal of Clinical Pathology</i> , 2016 , 69, 266-70	3.9	25
87	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , 2016 , 57, 717-20	1.9	11
86	Acute myeloid leukaemia: expression of MYC protein and its association with cytogenetic risk profile and overall survival. 2017 , 35, 350-356		12
85	Polymorphisms in key regulator genes of the intrinsic apoptosis pathway in risk and clinical presentation of diffuse large B-cell lymphoma. 2017 , 35, 911-913		
84	Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. 2017 , 12, 3		8
83	Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6. 2017 , 213, 659-665		4
82	Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2403-2418	1.9	11
81	Impact of cachexia on outcomes in aggressive lymphomas. 2017 , 96, 951-956		10
80	BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. 2017 , 130, 489-500		43
79	T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells. 2017 , 10, 116		15
78	Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. 2017 , 10, 277-284		18
77	Immunohistochemical Profile of MYC Protein in Pediatric Small Round Blue Cell Tumors. 2017 , 20, 213-223		9
76	Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. 2017 , 60, 6587-6597		25
75	Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. 2017 , 129, 280-288		98
74	MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL. 2017 , 76, 942-948		14
73	Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings. <i>British Journal of Haematology</i> , 2017 , 178, 871-887	4.5	31

72	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. 2017 , 35, 24-31		105
71	BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy. 2017 , 15, 1269-1279		10
70	Association of BAX G(-248)A and BCL2 C(-717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients. <i>British Journal of Haematology</i> , 2017 , 177, 650-654	4.5	3
69	High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. 2017 , 31, 37-42		119
68	Aggressive lymphoma 2016: revision of the WHO classification. 2017 , 10, 248-254		23
67	Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?. 2017 , 2017, 284-294		16
66	Advances in Pathobiology of Primary Central Nervous System Lymphoma. 2017 , 130, 1973-1979		6
65	Role of MYC in B Cell Lymphomagenesis. 2017 , 8,		14
64	Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence. <i>PLoS ONE</i> , 2017 , 12, e0172364	3.7	9
63	Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis. 2018 , 8, 6267		18
62	Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. 2018 , 24, 3967-3980		48
61	Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. 2018 , 32, 400-415		28
60	MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1391-1398	1.9	7
59	Clinical significance and functional validation of inorganic pyrophosphatase in diffuse large B cell lymphoma in humans. 2018 , 70, 641-649		5
58	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. 2018 , 24, 514-520		27
57	A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2018 , 103, 288-296	6.6	12
56	Acute Myeloid Leukemia (AML): Upregulation of BAALC/MN1/MLLT11/EVI1 Gene Cluster Relate With Poor Overall Survival and a Possible Linkage With Coexpression of MYC/BCL2 Proteins. 2018 , 26, 483-488		3
55	Double-hit and double-expressor B-cell lymphomas: Current treatment strategies and impact of hematopoietic cell transplantation. 2018 , 1, e13		2

54	BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma. 2018 , 140, 115-121		10
53	Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e381-e389	2	10
52	Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 806-811	2	2
51	A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma. 2019 , 14, 100		4
50	The role of autologous stem cell transplantation in diffuse large B-cell lymphoma. 2019 , 2, e33		1
49	Double-hit lymphoma: So what?. 2019 , 37 Suppl 1, 19-23		10
48	Autologous hematopoietic stem cell transplantation as first-line consolidation therapy can improve the prognosis of diffuse large B-cell lymphoma with high expression of MYC protein. 2019 , 35, 425-431		1
47	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. 2019 , 37, 1790-1799		156
46	Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma. 2019 , 12, 699-707		9
45	Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?. 2019 , 3, e284		7
44	Immunohistochemical overexpression of BCL-2 protein predicts an inferior survival in patients with primary central nervous system diffuse large B-cell lymphoma. 2019 , 98, e17827		2
43	Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas. <i>Human Pathology</i> , 2019 , 83, 124-132	3.7	4
42	Pearls and pitfalls in the diagnostic workup of small lymph node biopsies. <i>Modern Pathology</i> , 2019 , 32, 38-43	9.8	1
41	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019 , 33, 1047-1051	10.7	12
40	Clinical significance of 'double-hit' and 'double-expression' lymphomas. <i>Journal of Clinical Pathology</i> , 2020 , 73, 126-138	3.9	8
39	As the world turns, evolving lymphoma classifications-past, present and future. <i>Human Pathology</i> , 2020 , 95, 55-77	3.7	11
38	Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma. <i>Proteomics - Clinical Applications</i> , 2020 , 14, e1900091	3.1	7
37	Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling. <i>BMC Cancer</i> , 2020 , 20, 1017	4.8	3

36	Immunophenotypic Landscape and Prognosis of Diffuse Large B-Cell Lymphoma with MYC/BCL2 Double Expression: An Analysis of A Prospectively Immunoprofiled Cohort. <i>Cancers</i> , 2020 , 12,	6.6	2
35	Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma. <i>NAR Cancer</i> , 2020 , 2, zcaa029	5.2	5
34	Generation of a Murine Model for c-MYC and BCL2 Co-expression B Cell Lymphomas. <i>Frontiers in Oncology</i> , 2020 , 10, 1007	5.3	1
33	Spontaneous Regression of High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements: Case Report and Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e120-e125	2	1
32	New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL). <i>Brain and Behavior</i> , 2021 , 11, e02061	3.4	1
31	Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 246-256.e2	2	0
30	Fluorescent nanoparticle-mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B-cell lymphoma. <i>Pathology International</i> , 2021 , 71, 594-603	1.8	
29	Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. <i>Haematologica</i> , 2021 ,	6.6	1
28	The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	2
27	Testicular Diffuse Large B-Cell Lymphoma-Clinical, Molecular, and Immunological Features. <i>Cancers</i> , 2021 , 13,	6.6	3
26	Pathology and Molecular Pathogenesis of DLBCL and Related Entities. <i>Methods in Molecular Biology</i> , 2019 , 41-73	1.4	1
25	PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. <i>Journal of Clinical Investigation</i> , 2018 , 128, 5517-5530	15.9	49
24	MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. <i>PLoS ONE</i> , 2014 , 9, e104068	3.7	31
23	Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016 , 7, 86433-86445	3.3	31
22	Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018 , 19, 1229-1236	1.7	6
21	MYC in addition to BCL2 or BCL6 protein coexpression Double-expressor contributes to the inferior overall survival in a series of Egyptian patients with diffuse large B-cell lymphoma. <i>Egyptian Journal of Pathology</i> , 2018 , 38, 84-91	0	
20	Standard of Care in First-Line Therapy of DLBCL. <i>Technik Im Fokus</i> , 2019 , 145-155	0.3	
19	The prognostic importance of double-expressor subgroup and AID , UNG and mismatch repair protein expressions in diffuse large B-cell lymphomas. <i>Marmara Medical Journal</i> ,		

18	50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?. <i>Surgical and Experimental Pathology</i> , 2020 , 3,	1.6	0
17	Prevalence and prognostic value of and mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma. <i>British Journal of Ophthalmology</i> , 2021 ,	5.5	
16	Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study. <i>Journal of Clinical Pathology</i> , 2021 , 74, 816-818	3.9	
15	Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined With Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2021 ,	6.7	
14	Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 7559-64	1.4	1
13	The impact of protein expression and gene abnormality on primary central nervous system diffuse large B-cell lymphoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2019 , 12, 2215-2223	1.4	4
12	[Prognostic analysis of BCL-2/MYC double- hit in diffuse large B-cell lymphoma]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , 2015 , 36, 656-61	0.4	0
11	[Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , 2019 , 40, 589-593	0.4	0
10	[The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , 2021 , 42, 124-128	0.4	4
9	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?. <i>Leukemia and Lymphoma</i> , 2021 , 1-11	1.9	0
8	Ki67 Immunohistochemical Expression Level $\geq 70\%$, Bulky Presentation ≥ 5 cm, Meningeal Lymphomatosis, and Interim PET SUVmax After 4 Treatment Cycles $\geq 71\%$ as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma. 2022 , 2,		1
7	Image_1.TIFF. 2020 ,		
6	Image_2.TIFF. 2020 ,		
5	Image_3.TIFF. 2020 ,		
4	Image_4.TIFF. 2020 ,		
3	Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022 , 13,	8.4	0
2	R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022 ,	2	1
1	Identification of MYC/BCL2 Double-expressers Lymphomas in Diffuse Large B Cell Lymphoma Patients and Association with their Prognostic Parameters and Survival Rates: A Single Centre Experience. 2022 , 18, 87-92		0

